CAS: 41806-40-0; 1-Methylimidazole-5-Carboxylic Acid

该化合物是一种有机化合物,其特征是其imidazole环结构,即五人组成的含有两个氮原子的环环环,该化合物在Idiidazole环和甲基组(-CH3)的5个位置上具有碳酸性功能组(-COOH),这些功能组的存在有助于其酸性以及氢联结潜力,影响极地溶剂中的溶解性.它通常是白色至非白色固体的,由于碳白酸组的极性,在水中可溶性.该化合物可能在不同领域,包括制药和生物化学学领域,因其潜在的生物活动以及作为合成更复杂分子的建筑块的作用而引起兴趣.它的独特结构使得它能够产生各种化学反应,从而在有机合成中成为多用途化合物.

英文名称1-Methylimidazole-5-Carboxylic Acid
中文名称1-甲基咪唑-5-甲酸
IUPAC名称1-methyl-1H-imidazole-5-carboxylic acid
其它别名1-Methylimidazole-5-Carboxylic Acid; 1-Methyl-5-Imidazolecarboxylic Acid; 3-Methyl-3H-Imidazole-4-Carboxylic Acid; 1-Methyl-1H-Imidazole-5-Carboxylic Acid; Pbedvtduvxfsmw-
CAS编号41806-40-0
MFCD编号:MFCD00955677
EINECS号:670-292-8
分子式:C5H6N2O2
分子量:126.11
产品CID: 1431892
产品分类医药中间体

相似结构搜索
产品信息参考;;;;
InChIKey: PBEDVTDUVXFSMW-UHFFFAOYSA-N
InChI=1S/C5H6N2O2/c1-7-3-6-2-4(7)5(8)9/h2-3H,1H3,(H,8,9)…
计算化学: 氢键受体数3.0氢键供体数1.0可旋转键数1.0

MSDS等安全信息

GHS象形图
GHS符号GHS07;
注释: Exclamation mark
危险类别严重眼刺激类别2
皮肤腐蚀/刺激类别2
急性毒性类别4(吸入)
急性毒性类别4(经皮)
急性毒性类别4(经口)
特定目标器官毒性 - 单次接触类别3
严重眼刺激类别2A
警示词Warning(警告)
危险描述H319 |造成严重眼刺激.
H315 |造成皮肤刺激.
H332 |吸入有害.
H312 |皮肤接触有害.
H302 |吞咽有害.
H335 |可能引起呼吸道刺激.
防范说明P305+P351+P338
危险等级IRRITANT
危险品标志Xi
安全声明26-36/37/39-37/39
危险类别码36/37/38-36
WGK Germany3

欧盟法规

ECHA物质C&L通报

上下游产品

1-甲基咪唑-5-甲酸甲酯 Methyl 1-Methyl-1H-Imidazole-5-Carboxylate 17289-20-2
1-甲基咪唑-5-甲酸乙酯 Ethyl 1-Methyl-1H-Imidazole-5-Carboxylate 66787-70-0
1-甲基-1H-咪唑-4,5-二羧酸 1-Methyl-4,5-Imidazoledicarboxylic Acid 19485-38-2

合成工艺路线路线简述

1-甲基-1H-咪唑-4,5-二羧酸置于乙酸酐体系中,化学反应 4.0H,以99%的收率获得产物1-甲基-1H-咪唑-5-甲酸
参考文献:Selective Decarboxylation Of 1-Methyl-4,5-Imidazoledicarboxylic Acid
标题:Selective Decarboxylation Of 1-Methyl-4,5-Imidazoledicarboxylic Acid
摘要:在各种溶剂中对 1-甲基-4,5-咪唑二羧酸进行了选择性脱羧.1-甲基-5-咪唑羧酸是在乙酸酐或丙酸酐中加热得到的,而 1-甲基-4-咪唑羧酸则是在 N,N'-二甲基甲酰胺,N,N'-二甲基乙酰胺或 N-甲基吡咯烷酮中或通过热解得到的.讨论了反应机理.
DOI:10.1246/bcsj.53.557

海关参考信息

2905110000-甲醇
2912110000-甲醛
2915110000-甲酸
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-2025223262-A1
优先权日:2022-03-31
标题 :Synthesis of morphinans with reduced herg activity and mop binding
发明人：LAMMERT ECKHARD; SCHOLZ OKKA; OTTER SILKE; HEREBIAN DIRAN; HOFFMANN TORSTEN; SANZ MIGUEL ANGEL; KRAMP LAURENZ; LEVY LAURA MARIANA; HRISTEVA STANIMIRA
权利人:HEINRICH HEINE UNIV DUESSELDORF; DEUTSCHE DIABETES FORSCHUNGSGESELLSCHAFT E V; TAROS CHEMICALS GMBH & CO KG
摘要:The invention relates to morphinan-derivatives, processes for their preparation, medicaments containing them and the use of these morphinan-derivatives for the preparation of medicaments.

专利号:EP-4499223-A1
优先权日:2022-03-31
标题 :Synthesis of morphinans with reduced herg activity and mop binding

专利号:RU-2024510-C1
优先权日:1988-06-23
标题 :Method of synthesis of nitrogen-containing heterocyclic compounds

专利号:WO-2023187099-A1
优先权日:2022-03-31
标题 :Synthesis of morphinans with reduced herg activity and mop binding

专利号:HU-T78019-A
优先权日:1995-03-31
标题 :A method for the synthesis of substituted nitrogen-containing heterocyclic compounds

专利号:US-2008139558-A1
优先权日:2006-02-24
标题 :Quinolones useful as inducible nitric oxide synthase inhibitors
发明人：SMITH NICHOLAS D; ROPPE JEFFREY R; BONNEFOUS CELINE; PAYNE JOSEPH E; ZHUANG HUI; CHEN XIAOHONG; LINDSTROM ANDREW K; DURON SERGIO G; HASSIG CHRISTIAN A; NOBLE STEWART A
权利人:KALYPSYS INC
摘要:The present invention relates to novel quinolones of Formula I that inhibit inducible NOS synthase together with methods of synthesizing and using the compounds including methods for inhibiting or modulating nitric oxide synthesis and/or lowering nitric oxide levels in a patient by administering the compounds for the treatment of disease.